COMMUNIQUÉS West-GlobeNewswire

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
29/10/2025
- $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, [...]
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
29/10/2025
TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”) TX45 was well tolerated in patients with PH‑ [...]
Veru Announces Proposed Public Offering
29/10/2025
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
29/10/2025
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned [...]
Patients demand Ford government reimburse wrongful charges at Ford’s private clinics: more than 160 people join Day of Action at Ontario Legislature
29/10/2025
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Patients who have been wrongfully charged for surgeries and diagnostic tests at private clinics were joined by more than 160 supporters at the Ontario Legislature today for a “ [...]
RAMSAY SANTE : availability of the Universal Registration Document 2025
29/10/2025
PRESS RELEASE Paris, 29 th October 2025 AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT 2025 Ramsay Générale de Santé's 2025 Universal Registration Document was filed with the Autorité des marchés financiers (AMF) [...]
RAMSAY SANTE : communiqué de mise à disposition du document d'enregistrement universel 2025
29/10/2025
COMMUNIQUÉ DE PRESSE Paris, le 29 octobre 2025 COMMUNIQUÉ DE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2025 Le Document d’enregistrement universel 2025 de Ramsay Générale de Santé a été déposé auprès de [...]
EmblemHealth and Prime Therapeutics Pioneer New Pharmacy Benefit Collaboration
29/10/2025
Unique partnership, in collaboration with Amazon Pharmacy and Judi Health, brings transparent pricing, digital convenience, and fast, free home delivery of prescription medications for members NEW YORK, Oct. 29, 2025 ( [...]
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
29/10/2025
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
CORRECTION – Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield
29/10/2025
NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Wednesday, October 29th by Solana Company (NASDAQ: HSDT), please note that in the first sentence of the third paragraph, the [...]
Curia publie son rapport ESG (environnement, social et gouvernance) 2024
29/10/2025
ALBANY, New York, 29 oct. 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui la publication de [...]
Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025
29/10/2025
- First-in-human data validating direct targeting of NETs as a novel therapeutic approach in autoimmunity and inflammatory diseases - DNASE1L3 analogue therapy degrades NETs and results in rapid, multi-organ clinical [...]
Virginia Cannabis Dispensary Cannisco Unveils New Brand Identity as East Coast Collective Transitions
29/10/2025
Shenandoah Valley-Based Hemp Company Rebrands to Reflect Commitment to Quality, Integrity, and Seed-to-Sale Excellence Shenandoah Valley, Virginia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Cannisco , formerly East Coast [...]
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
29/10/2025
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living [...]
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
29/10/2025
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results show ~60% of VYVGART [...]
Plum Tree Launches New Chronic Illness Therapy Program
29/10/2025
ST. CHARLES, Ill., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Plum Tree Psychology, Ltd., a leading child and family mental health practice in the Fox Valley, today announced the launch of Hoot & Holler, a new Chronic [...]
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
29/10/2025
NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit 1 Data showed consistent improvements across secondary outcome measures, and a favorable safety [...]

Pages